Loading stock data…
$2.32-0.12 (-4.92%)
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. in the Healthcare sector is trading at $2.32 with a market capitalization of $732M. Wall Street consensus targets $12.25 (8 analysts), implying a +428.0% move over the next 12 months. The stock is currently near its 52-week low of $2.20, remaining 40.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.42M↓ | $10.26M↑ | $663,000↓ | $5.96M↓ | $18.66M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.78M↓ | -$19.67M↑ | -$27.93M↓ | -$15.77M↓ | -$1.29M |
| Net Income | -$20.67M↓ | -$18.25M↑ | -$26.51M↓ | -$14.23M↓ | -$154,000 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...